Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries.

"CONFLICTS OF INTEREST Amélie Beaudet and Nadia Pillai are employees of Actelion Pharmaceuticals, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland. The remaining authors declare no conflict of interest."

"We acknowledge the work of the SPAHR registrars at the PAH/CTEPH‐specialist clinics, the members of the SPAHR steering committee, and Uppsala Clinical Research Center for administrating SPAHR. This study was funded by Actelion Pharmaceuticals, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland. Representatives of Actelion Pharmaceuticals, a Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland, listed as authors of this paper, participated in study design, interpretation of data, and drafting the manuscript, but did not participate in data analyses. Additional funding was received in terms of a scholarship from SveFPH/SPAHR. Guarantor: Lund University, Lund, Sweden."